At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 940 enrolled
Drug / intervention
Pazopanib +1 moredrug
Likely dose
Pazopanib 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
In Brief
A Phase 3 clinical trial evaluating Pazopanib and Placebo for Ovarian Cancer. Completed, enrolled 940 participants across 318 sites in 17 countries.
Detailed Summary
This was a study to determine whether therapy with pazopanib was effective and safe in women with epithelial ovarian, fallopian tube, or primary peritoneal cancer whose cancer had not progressed on first line chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesAustralia, Austria, Belgium, China, Denmark, France, Germany, Hong Kong, Ireland, Italy, Japan, Norway, South Korea, Spain, Sweden, Taiwan, United States
CollaboratorsGlaxoSmithKline
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2009
Enrollment StartMay 2009
Primary CompletionJul 2012
Study CompletionAug 2017
TodayJul 2026
First PostedMar 20, 2009
Enrollment StartMay 26, 2009
Primary CompletionJul 8, 2012
Study CompletionAug 24, 2017
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 17.3 years ago
Interventions
Pazopanibdrug
Pazopanib 800 mg tablet daily for 104 weeks (24 months)
Placebodrug
Matching placebo 800 mg tablet daily, for 104 weeks (24 months).